Drug company Biogen Inc. intends to pursue regulatory approval from the Food and Drug Administration (FDA) for their experimental Alzheimer’s drug, aducanumab, based on new analyses of data from their Phase 3 clinical trials. The study results showed reduced decline in people with mild cognitive impairment and mild dementia due to Alzheimer’s disease who received the highest dose of the drug over a sufficient period of time.
Dr. Ronald Petersen, director of the Alzheimer’s Disease Research Center at Mayo Clinic, says aducanumab targets the amyloid plaques in the brain that are believed to be an essential component of Alzheimer’s disease.
More health and medical news on the Mayo Clinic News Network. https://newsnetwork.mayoclinic.org/
Journalists: Clean and nat sound versions of this pkg available for download at https://newsnetwork.mayoclinic.org/
Register (free) at https://newsnetwork.mayoclinic.org/request-account/